Chardan Capital Lowers Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $17.00
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target reduced by research analysts at Chardan Capital from $46.00 to $17.00 in a report released on Wednesday, MarketBeat.com reports. The firm presently has a “buy” rating on the biotechnology company’s stock. RCKT has been the topic of several other research reports. Jefferies Financial Group […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target reduced by research analysts at Chardan Capital from $46.00 to $17.00 in a report released on Wednesday, MarketBeat.com reports. The firm presently has a “buy” rating on the biotechnology company’s stock. RCKT has been the topic of several other research reports. Jefferies Financial Group […]
